GlassScriptPhysician profile
Gabriel Sandoval
NPI 1720585474
$2,800.81
in general payments reported to CMS, 2019-2025
18 companies · $891 in 2025
The $891 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $290 · 2023: $762 · 2024: $859 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.07 | 2022-2025 | Linzess, Viberzi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $584.67 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.65 | 2022-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $217.97 | 2023-2024 | Dificid |
| Conmed Corporation | $213.02 | 2022-2025 | Conmed Generators |
| Janssen Biotech, INC. | $142.80 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $108.56 | 2024-2025 | |
| Madrigal Pharmaceuticals | $70.86 | 2025 | Rezdiffra |
| Orphalan INC | $66.14 | 2023-2024 | Cuvrior |
| Celgene Corporation | $53.17 | 2023 | Zeposia |
| Genzyme Corporation | $50.97 | 2023-2024 | |
| Boston Scientific Corporation | $49.87 | 2023-2025 | Orise, Watchman Access System, Overstitch Endoscopic Suturing System |
| Qol Medical, LLC | $31.09 | 2023 | Sucraid |
| Apollo Endosurgery US INC | $28.40 | 2022 | |
| Alcresta Therapeutics, INC. | $21.07 | 2023 | Relizorb |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $19.41 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $19.03 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $16.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.